UniSa - IRIS Institutional Research Information System

PERSICO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 14.977
NA - Nord America 10.526
EU - Europa 3.210
SA - Sud America 974
AF - Africa 167
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 9
Totale 29.883
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.308
HK - Hong Kong 9.739
SG - Singapore 2.383
CN - Cina 1.179
BR - Brasile 742
VN - Vietnam 705
UA - Ucraina 645
IT - Italia 629
RU - Federazione Russa 431
DE - Germania 352
FR - Francia 246
IE - Irlanda 245
KR - Corea 230
FI - Finlandia 176
TR - Turchia 173
SE - Svezia 132
CA - Canada 118
GB - Regno Unito 112
IN - India 110
AR - Argentina 90
JP - Giappone 80
BD - Bangladesh 75
MX - Messico 63
ZA - Sudafrica 56
IQ - Iraq 49
ID - Indonesia 39
NL - Olanda 39
EC - Ecuador 37
ES - Italia 35
AT - Austria 33
VE - Venezuela 30
CO - Colombia 28
PL - Polonia 28
PK - Pakistan 27
DK - Danimarca 26
SA - Arabia Saudita 20
MA - Marocco 18
MY - Malesia 18
EG - Egitto 17
UZ - Uzbekistan 17
PY - Paraguay 16
AU - Australia 15
TW - Taiwan 15
PH - Filippine 14
AZ - Azerbaigian 12
DZ - Algeria 12
AE - Emirati Arabi Uniti 11
CZ - Repubblica Ceca 11
JO - Giordania 11
LT - Lituania 11
TN - Tunisia 11
IL - Israele 10
PE - Perù 10
AL - Albania 9
CL - Cile 9
KE - Kenya 9
JM - Giamaica 8
KZ - Kazakistan 8
PS - Palestinian Territory 8
RO - Romania 8
OM - Oman 7
SN - Senegal 7
EU - Europa 6
HN - Honduras 6
PT - Portogallo 6
BE - Belgio 5
BO - Bolivia 5
CH - Svizzera 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
UG - Uganda 5
BH - Bahrain 4
CG - Congo 4
GR - Grecia 4
GT - Guatemala 4
LB - Libano 4
NO - Norvegia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
TH - Thailandia 4
AO - Angola 3
BG - Bulgaria 3
BS - Bahamas 3
CI - Costa d'Avorio 3
ET - Etiopia 3
GY - Guiana 3
IR - Iran 3
LY - Libia 3
ME - Montenegro 3
MW - Malawi 3
PA - Panama 3
QA - Qatar 3
RS - Serbia 3
AF - Afghanistan, Repubblica islamica di 2
BJ - Benin 2
BN - Brunei Darussalam 2
BW - Botswana 2
CW - ???statistics.table.value.countryCode.CW??? 2
GE - Georgia 2
HR - Croazia 2
Totale 29.849
Salva come PNG Salva come JPEG
Città #
Hong Kong 9.691
Ann Arbor 1.681
Singapore 1.235
San Jose 1.073
Chandler 838
Jacksonville 819
Princeton 723
Ashburn 536
Woodbridge 520
Dallas 452
Wilmington 366
Houston 302
Beijing 257
Council Bluffs 255
The Dalles 254
Dublin 237
Dong Ket 217
Lauterbourg 204
Andover 164
Ho Chi Minh City 163
Nanjing 147
Izmir 143
Pellezzano 128
Boardman 122
Los Angeles 115
Hanoi 109
Moscow 95
New York 85
Munich 75
São Paulo 66
Naples 65
Salerno 65
Tokyo 62
Santa Clara 59
Hebei 55
Shenyang 54
Ottawa 47
Changsha 45
Fairfield 45
Columbus 43
Nanchang 42
Norwalk 42
Jiaxing 39
Montreal 37
Brooklyn 35
Frankfurt am Main 34
Düsseldorf 33
Redwood City 33
Nuremberg 31
Johannesburg 30
Stockholm 30
Tianjin 29
Chennai 28
Jinan 28
Denver 27
Orem 26
Turku 26
Washington 26
London 25
Mestre 25
Mexico City 25
Haiphong 24
Da Nang 23
Rio de Janeiro 23
Warsaw 23
Belo Horizonte 22
Chicago 22
Seattle 22
Guangzhou 21
Amsterdam 20
Atlanta 20
Dhaka 20
Falls Church 20
Phoenix 20
Boston 19
Dearborn 19
Brasília 18
San Diego 18
Helsinki 17
Baghdad 16
Curitiba 16
Tashkent 15
Vienna 14
Caracas 13
Lappeenranta 13
Manchester 13
Nürnberg 13
Rome 13
San Francisco 13
Biên Hòa 12
Cambridge 12
Guayaquil 12
Milan 12
Poplar 12
Pune 12
Seoul 12
Zhengzhou 12
Baku 11
Copenhagen 11
Shanghai 11
Totale 22.902
Salva come PNG Salva come JPEG
Nome #
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project) 954
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 759
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 758
Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case Series 712
Non Alcoholic Fatty Liver: Epidemiology and Natural History 620
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 599
Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control 565
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 517
Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects. 501
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 432
Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. 413
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 381
Prospective validation of the CLIP score: a new prognostic system for patient with cirrhosis and hepatocellular carcinoma 376
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 369
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 362
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 341
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 320
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma 314
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 312
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 310
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 297
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of early response in a primary hepatic lymphoma 290
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. 283
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 279
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 263
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 202
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 190
The diagnostic conundrum in non-alcoholic fatty liver disease 188
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 186
Management of adults with paediatric-onset chronic liver disease: Strategic issues for transition care 183
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 177
Non-ulcer dyspepsia and Helicobacter pylori in type 2 diabetic patients: association with autonomic neuropathy. 175
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 150
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 149
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection 149
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 148
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 147
Coeliac disease and C virus-related chronic hepatitis: a non association 147
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. 144
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 143
Timed regulation of P-Element-Induced Wimpy Testis-interacting RNA expression during rat liver regeneration. 142
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 142
Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. 137
[Hepatorenal syndrome. Clinical and pathogenetic aspects and therapeutic approach]. 136
Pharmacotherapy of alcoholic liver disease in clinical practice 136
Alcoholic Liver Disease and Hepatitis C Chronic Infection 136
Epidemiology and Natural History of Alcoholic Liver Disease 135
Adiponectin in hepatology 134
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 131
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 130
[Diabetic neuropathies. IV. Autonomous neuropathy. Peripheral sympathetic innervation and the cardiovascular system]. 128
Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. 128
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 128
A controlled trial on treatment of patients with HCV infection and abnormal liver function tests with or without liver biopsy 126
A 15-Yr Prospective Histological Follow-Up Study in Patients With Persistently Normal Aminotransferase Levels (PNAL) Carrying HCV Infection. 123
Age-associated decline of hepatic handling of cholephilic anions in humans is reverted by S-adenosylmethionine (SAMe). 123
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 123
Ultrasound-guided fine needle aspiration biopsy of portal vein thrombosis in liver cirrhosis: results in 15 patients. 122
A randomised controlled trial on pegylated interferon alfa-2a (40kd)(Pegasys) or IFN alfa-2a (ROFERON-A) plus ribavrin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naïve patients with chronic HCV 122
154 LOW RATE OF ONE-YEAR MORTALITY IN PATIENTS WITH STAGE 4 CIRRHOSIS: THE ITALIAN ASSOCIATION FOR THE STUDY OF LIVER (A.I.S.F.)-EPASCO PROSPECTIVE MULTICENTRE STUDY 122
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 120
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 120
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 119
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 118
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 116
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 115
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 115
A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis 114
93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study 114
478 Treating chronic hepatitis C in daily practice with PEG-IFN alfa2B and ribavirin. An Italian multicentre study 114
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 114
Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: what can be done about the present definition? 113
The aetiology of chronic hepatitis in Italy: results from a multicentre national study 113
Risk factors for hospital readmission of elderly patients. 112
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 112
Color ultrasound-guided fine needle cutting biopsy for the characterization of diffuse liver damage in critical bone marrow transplanted patients. 110
Electrophysiological evidence for Na+-coupled bicarbonate transport in cultured rat hepatocytes 110
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 110
Steatosis as a co-factor in chronic liver diseases 107
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. 107
Abnormal hepatic uptake of low doses of sulfobromophthalein in Gilbert's syndrome: the role of reduced affinity of the plasma membrane carrier of organic anions. 107
Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C 106
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 106
Na+-H+ exchange activity in rat hepatocytes: Role in regulation of intracellular pH 105
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 105
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 104
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 104
Viral hepatitis: Milestones, unresolved issues, and future goals 103
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 103
[Diabetic neuropathy. II. Autonomic neuropathy. The gastrointestinal system]. 102
Familial clustering of heterogeneous chronic unconjugated hyperbilirubinemia. 101
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 101
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 101
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. 100
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 100
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 100
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 99
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 99
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. 98
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 98
Totale 20.724
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.545
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.545
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021433 0 0 0 0 0 0 0 0 0 0 180 253
2021/20221.248 6 3 8 6 26 24 34 58 193 169 156 565
2022/20232.009 207 118 63 237 291 430 12 185 301 5 108 52
2023/2024890 82 120 69 32 71 140 32 44 8 34 51 207
2024/20252.756 73 46 56 118 152 290 434 323 486 170 291 317
2025/202616.898 1.663 4.630 4.623 550 1.186 593 1.750 346 548 911 98 0
Totale 30.261